RU2007128926A - Антагонисты 5ht7 рецепторов - Google Patents
Антагонисты 5ht7 рецепторов Download PDFInfo
- Publication number
- RU2007128926A RU2007128926A RU2007128926/04A RU2007128926A RU2007128926A RU 2007128926 A RU2007128926 A RU 2007128926A RU 2007128926/04 A RU2007128926/04 A RU 2007128926/04A RU 2007128926 A RU2007128926 A RU 2007128926A RU 2007128926 A RU2007128926 A RU 2007128926A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- unsubstituted
- compound according
- formula
- isomer
- Prior art date
Links
- 108091005436 5-HT7 receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000008967 Enuresis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04380279.2 | 2004-12-28 | ||
| EP04380279A EP1676844A1 (en) | 2004-12-28 | 2004-12-28 | 5-HT7 receptor antagonists |
| US11/048,992 US7345057B2 (en) | 2004-12-28 | 2005-02-02 | 5-HT7 receptor antagonists |
| US11/048,992 | 2005-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007128926A true RU2007128926A (ru) | 2009-02-10 |
Family
ID=34931894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007128926/04A RU2007128926A (ru) | 2004-12-28 | 2005-12-27 | Антагонисты 5ht7 рецепторов |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7345057B2 (https=) |
| EP (2) | EP1676844A1 (https=) |
| JP (1) | JP2008525513A (https=) |
| KR (1) | KR20070091040A (https=) |
| CN (1) | CN101090898A (https=) |
| AU (1) | AU2005321463A1 (https=) |
| BR (1) | BRPI0519792A2 (https=) |
| CA (1) | CA2590666A1 (https=) |
| MX (1) | MX2007007894A (https=) |
| RU (1) | RU2007128926A (https=) |
| WO (1) | WO2006069776A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ552397A (en) | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| JP2010510324A (ja) * | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | がん療法のための治療用テトラヒドロイソキノリン系組成物 |
| ES2395872T3 (es) * | 2007-05-11 | 2013-02-15 | Eli Lilly And Company | 2-[4-(Pirazol-4-ilalquil)piperazin-1-il]-3-fenil pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor de 5-HT7 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| EP2375899B1 (en) * | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
| AU2010247763B2 (en) * | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
| GB201209587D0 (en) * | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2014202999A1 (en) * | 2013-06-21 | 2014-12-24 | Takeda Cambridge Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
| GB201420095D0 (en) | 2014-11-12 | 2014-12-24 | Takeda Pharmaceutical | New use |
| US11505529B2 (en) * | 2017-03-03 | 2022-11-22 | National Taiwan University | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| CN112083107B (zh) * | 2020-09-28 | 2022-07-05 | 中国计量科学研究院 | 检测蜂蜜基质中磺胺类药物葡萄糖醛酸结合物的方法 |
| TW202345813A (zh) | 2022-04-08 | 2023-12-01 | 美商艾科尼佐療法股份有限公司 | 㗁二唑ｈｄａｃ６抑制劑及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193654A (en) | 1979-05-16 | 1984-08-24 | Wuelfing Johann A | Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions |
| EP0076072B1 (en) | 1981-09-24 | 1987-05-13 | BEECHAM - WUELFING GmbH & Co. KG | Sulphonamides |
| EP0883613A1 (en) | 1996-02-09 | 1998-12-16 | Smithkline Beecham Plc | Sulfonamide derivatives as 5ht7 receptor antagonists |
| GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| EP0912550A1 (en) * | 1996-06-25 | 1999-05-06 | Smithkline Beecham Plc | Sulfonamide derivatives as 5ht7 receptor antagonists |
| WO1999024022A2 (en) | 1997-11-10 | 1999-05-20 | F. Hoffmann-La Roche Ag | Isoquinoline derivatives for treating disorders associated with 5ht7 receptors |
| AU4698299A (en) * | 1998-06-30 | 2000-01-17 | Du Pont Pharmaceuticals Company | 5-HT7 receptor antagonists |
| GB0128885D0 (en) | 2001-12-03 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
-
2004
- 2004-12-28 EP EP04380279A patent/EP1676844A1/en not_active Withdrawn
-
2005
- 2005-02-02 US US11/048,992 patent/US7345057B2/en not_active Expired - Fee Related
- 2005-12-27 RU RU2007128926/04A patent/RU2007128926A/ru not_active Application Discontinuation
- 2005-12-27 WO PCT/EP2005/014046 patent/WO2006069776A1/en not_active Ceased
- 2005-12-27 AU AU2005321463A patent/AU2005321463A1/en not_active Abandoned
- 2005-12-27 KR KR1020077017187A patent/KR20070091040A/ko not_active Withdrawn
- 2005-12-27 JP JP2007548747A patent/JP2008525513A/ja active Pending
- 2005-12-27 MX MX2007007894A patent/MX2007007894A/es not_active Application Discontinuation
- 2005-12-27 CA CA002590666A patent/CA2590666A1/en not_active Abandoned
- 2005-12-27 CN CNA2005800452243A patent/CN101090898A/zh active Pending
- 2005-12-27 EP EP05849072A patent/EP1831195B1/en not_active Expired - Lifetime
- 2005-12-27 BR BRPI0519792-9A patent/BRPI0519792A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101090898A (zh) | 2007-12-19 |
| JP2008525513A (ja) | 2008-07-17 |
| EP1831195B1 (en) | 2012-12-19 |
| AU2005321463A1 (en) | 2006-07-06 |
| BRPI0519792A2 (pt) | 2009-03-17 |
| MX2007007894A (es) | 2007-10-03 |
| US20060142332A1 (en) | 2006-06-29 |
| EP1831195A1 (en) | 2007-09-12 |
| US7345057B2 (en) | 2008-03-18 |
| EP1676844A1 (en) | 2006-07-05 |
| WO2006069776A1 (en) | 2006-07-06 |
| KR20070091040A (ko) | 2007-09-06 |
| CA2590666A1 (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007128926A (ru) | Антагонисты 5ht7 рецепторов | |
| JP2008513516A5 (https=) | ||
| US20030158216A1 (en) | 2-acyl indole derivatives and their use as antitumor agents | |
| KR100264807B1 (ko) | 혈관내막비후억제제 | |
| WO1999020620A1 (en) | Isoquinoline derivative and drug | |
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| US20230059381A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
| RU2002131885A (ru) | Антраниламиды и их применение в качестве лекарственных средств | |
| WO2016071283A1 (en) | Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase | |
| JP2007512299A5 (https=) | ||
| JP2005522439A5 (https=) | ||
| CN1159305C (zh) | 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物 | |
| US8871802B2 (en) | Naphthoquinones for disease therapies | |
| JP2005508969A5 (https=) | ||
| EP2636414A1 (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| WO2006088193A1 (ja) | 抗腫瘍剤 | |
| RU2006102867A (ru) | Производные 5-замещенного хиназолинона | |
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| WO2014127722A1 (zh) | 氮杂环取代二氢青蒿素衍生物及其应用 | |
| ES2399393T3 (es) | Compuestos de ácido carboxílico y composiciones medicinales que los contienen como principio activo | |
| US6638928B1 (en) | Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines | |
| JPS58219166A (ja) | ４−キノロン誘導体 | |
| WO2015002755A2 (en) | Compounds for the treatment of malaria | |
| RU2008110498A (ru) | Комбинация снотворного средства и замещенного соединения бис арила и гетероарила и ее терапевтическое применение | |
| RU2007128964A (ru) | Антагонисты рецепторов 5-ht7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100203 |